Sectors: Health, Research
Beneficiaries: Corporations, Research centres
Regions: European Union
Category: Call for proposals
References:To view this information, please connect.
Responsible: European commission
Useful:To view this information, please connect.
Contact:To view this information, please connect.
Advice:To view this information, please connect.
This call for proposals aims to develop a translational research project for the induction and monitoring of immune tolerance in rheumatoid arthritis.
Priorities and funded actions:
Work package 1: Management, coordination, dissemination and sustainability
– Overall coordination of the scientific work packages, budgets, delivery and dissemination of findings and sustainability planning.
Work package 2: Technologies for monitoring immune state.
– Deep immunophenotyping of patient samples using state of the art technologies such as T cell specificity using tetramers, autoantibody profiling and others.
Work package 3: Patients, cohorts and ethics
– Analysis of retrospective and design and prosecution of prospective clinical trials.
Work package 4: Mechanisms of immune tolerance – basic research
– Detailed analysis of patient tissues and samples to identify novel targets and pathways relevant to immune tolerance.
Work package 5: Bioinformatics and data
– Integration of historic and prospective data for the identification of biomarkers, stratification of patient cohorts and potentially new clinical targets.
Among financed actions
– Development of ‘companion diagnostics’ that make it possible to recognise specific immune reactions in different subsets of patients with RA and other relevant inflammatory disease including lupus and myositis.
– Development of tools for immuno-monitoring of T and B cell numbers and phenotype, as well as for other relevant immune and non-immune cell types. These tools should enable the evaluation of immunological effects of potential tolerance-inducing therapies.
– Identification of relevant RA patient cohorts that would be suitable for testing ‘tolerising’ therapies. Patient selection could be based on genetics, response to therapy, immune phenotype and auto-antibody profiles for example.
– Conduct experimental medicine studies using a small number of carefully selected RA patients to monitor changes in immunity following therapeutic intervention.